Palbociclib (PD-0332991) restrains HCC growth in a genetically engineered mosaic mouse model (Myc; p53-sgRNA) and extends the survival time of mice with human HCC xenografts, the therapeutic effect of which depends on the normal functionality of RB1 gene in tumor cells [103]. The gene discussed is MYC; the disease is hepatocellular carcinoma.